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capnia during non-invasive ventilation
Lise Piquilloud1*, David Thevoz1,2, Philippe Jolliet1 and Jean-Pierre Revelly1Abstract
Background: In acute respiratory failure, arterial blood gas analysis (ABG) is used to diagnose hypercapnia. Once
non-invasive ventilation (NIV) is initiated, ABG should at least be repeated within 1 h to assess PaCO2 response to
treatment in order to help detect NIV failure. The main aim of this study was to assess whether measuring end-tidal
CO2 (EtCO2) with a dedicated naso-buccal sensor during NIV could predict PaCO2 variation and/or PaCO2 absolute
values. The additional aim was to assess whether active or passive prolonged expiratory maneuvers could improve
the agreement between expiratory CO2 and PaCO2.
Methods: This is a prospective study in adult patients suffering from acute hypercapnic respiratory failure (PaCO2≥
45 mmHg) treated with NIV. EtCO2 and expiratory CO2 values during active and passive expiratory maneuvers were
measured using a dedicated naso-buccal sensor and compared to concomitant PaCO2 values. The agreement
between two consecutive values of EtCO2 (delta EtCO2) and two consecutive values of PaCO2 (delta PaCO2)
and between PaCO2 and concomitant expiratory CO2 values was assessed using the Bland and Altman
method adjusted for the effects of repeated measurements.
Results: Fifty-four datasets from a population of 11 patients (8 COPD and 3 non-COPD patients), were included in
the analysis. PaCO2 values ranged from 39 to 80 mmHg, and EtCO2 from 12 to 68 mmHg. In the observed agreement
between delta EtCO2 and deltaPaCO2, bias was −0.3 mmHg, and limits of agreement were −17.8 and 17.2 mmHg. In
agreement between PaCO2 and EtCO2, bias was 14.7 mmHg, and limits of agreement were −6.6 and 36.1 mmHg.
Adding active and passive expiration maneuvers did not improve PaCO2 prediction.
Conclusions: During NIV delivered for acute hypercapnic respiratory failure, measuring EtCO2 using a dedicating
naso-buccal sensor was inaccurate to predict both PaCO2 and PaCO2 variations over time. Active and passive expiration
maneuvers did not improve PaCO2 prediction.
Trial registration: ClinicalTrials.gov: NCT01489150.
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Non-invasive ventilation (NIV) is widely used [1] in emer-
gency rooms, in intensive and intermediate care units, and
in recovery rooms to treat de novo and, even if it is more
debatable [2,3], postextubation hypercapnic respiratory
failure. Arterial blood gas analysis (ABG) is usually per-
formed to diagnose hypercapnia and should at least be* Correspondence: lise.piquilloud@chuv.ch
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in any medium, provided the original work is prepeated within 1 h after NIV initiation to assess PaCO2
response to treatment [1]. However, as follow-up ABG re-
quires a new arterial puncture in patients not previously
equipped with an arterial line, this exam is often post-
poned with the risk of delaying NIV failure diagnosis and
intubation, a condition previously associated with poor
outcome [4]. Only a reliable non-invasive monitoring of
the course of PaCO2 during NIV could avoid such a
delay and help optimizing ventilator settings. End-tidal
CO2 (EtCO2) monitoring is easy to perform and widely
used during anesthesia to assess the adequacy of deliveredis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Naso-buccal sensor. Illustration of the naso-buccal sensor
used in this study. This device is designed to collect expiratory gas
immediately at the airway opening both at the nose and mouth levels.
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Using capnometry to monitor capnia in non-intubated
patients during NIV is much more challenging. Indeed,
during NIV, gas leak occurs in the respiratory ‘circuit’
and conceivably, in this situation, only gas sampling dir-
ectly at the level of the patient’s airways can reflect true
expiratory gas.
As new specialized naso-buccal EtCO2 sensors have
recently been developed to collect expired gas directly at
the airway opening, there is now an opportunity to use
capnometry to monitor capnia during NIV. The main
aim of this study was to assess the ability of a dedicated
EtCO2 naso-buccal sensor to predict PaCO2 variations
and/or PaCO2 absolute values in hypercapnic patients
during NIV. The second aim of the study was to assess
whether active or passive prolonged expiratory maneu-
vers could improve the agreement between expiratory
CO2 and PaCO2.
Methods
A prospective pilot study was conducted in our medico-
surgical ICU in Lausanne, Switzerland. The hospital
ethics committee (Human Research Ethics Committee of
Lausanne, Switzerland) approved the study protocol, and
written informed consent was obtained before inclusion in
the study. In the absence of published data reporting the
use of a naso-buccal sensor to measure EtCO2 in acutely
ill patients undergoing NIV, no power computation could
be performed.
Patients
Non-intubated patients suffering from hypercapnic
(PaCO2 ≥ 45 mmHg) acute respiratory failure, hospi-
talized in the ICU, equipped with an arterial line and
requiring NIV could be included in the study if they
had no major hemodynamic instability, no facial lesion
preventing the use of the naso-buccal sensor, and no cog-
nitive disability or psychiatric disease liable to interfere
with NIV. To note, as only patients admitted in the ICU
and already equipped with an arterial line could be in-
cluded in the study, the NIV treatment monitored in the
study was usually not the first NIV treatment delivered to
the patients.
Study protocol and measurements
Upon inclusion, the patient was equipped with the Smart
CapnoLine® naso-buccal sensor (Figure 1) designed to
collect expiratory gas immediately at the airway open-
ing both at the nose and mouth levels connected to
the Capnostream 20 monitor® (Oridion Medical Ltd,
Jerusalem, Israël). To perform the measurement, a sample
of gas is transmitted from the patient to a micro-cell of
15 μl located in the monitor (sidestream capnography
system). A sample of gas of 50 ml/min is needed forthe measurement. The measurement is performed by non-
dispersive infrared spectroscopy. For each respiratory cycle,
the capnogram is displayed on the Capnostream 20 moni-
tor®. For each EtCO2 value recorded, the investigator
checked the good quality of the capnogram displayed on
the screen. The value of one respiratory cycle was recorded
at each measurement time.
ABG and the corresponding EtCO2 value displayed by
the monitor were recorded as baseline values. NIV treat-
ment was then initiated using an hermetic naso-buccal
mask (Vygon Large®, Ecouen, France) held in place using
a dedicated strap and a single-limb NIV ventilator (V60®,
Respironics Philips, Amsterdam, Netherland). Calibrated
intentional leakage to allow CO2 expiration was created
in the respiratory circuit using the dedicated whisper
swivel (Whisper swivel®, Respironics Philips, Amsterdam,
Netherland). A flow sensor (Hamilton, Bonaduz, Switzerland)
was placed between the patient and the whisper swivel
and connected to an analog-to-digital converter (MP100,
Biopac, Systems, Goleta, CA, USA) to continuously record
the flow-time curve. The respiratory circuit with the add-
itional flow sensor is schematized in Figure 2. ABG and
EtCO2 values were recorded at 15, 30, 45, and 60 min
after the initiation of NIV. At times corresponding to each
PaCO2 and EtCO2 measurements, insufflated volumes
were measured offline for ten consecutive respiratory cy-
cles (by integration of the inspiratory flow-time curve re-
corded by the flow sensor placed between the patient and
the whisper swivel) and the mean value was computed.
Figure 2 Respiratory circuit. Illustration of the respiratory circuit used in the study. From the patient to the ventilator, the circuit consists of an
hermetic nasobuccal mask, the dedicated proximal flow sensor of the V60 ventilator, the additional flow sensor inserted to record insufflated
and exuflated flow-time curves, the dedicated whisper swivel to create a calibrated intentional leak to avoid CO2 rebreathing, and the
ventilator single-limb pipe.
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also computed.
At 30 and 60 min after the beginning of NIV, the patient
performed upon request a voluntary slow and maximal
expiration. In brief, the patients were asked to slowly
empty their lungs as much and for as long as possible.
The expired CO2 value displayed at the end of this active
expiration maneuver was recorded. A passive expiratory
maneuver was then performed with the help of an experi-
enced respiratory therapist (bilateral chest compression
during slow expiration), and the corresponding expired
CO2 value was recorded. The naso-buccal mask was not
removed during the maximal expiratory maneuvers mean-
ing that the patient expired through the nasobuccal sensor
and the ventilator circuit and thus against the set PEEP.
The backup safety respiratory frequency of the ventilator
was set at 6 by minute to allow expiratory maneuvers
of 10 s.
Calculations and statistics
To assess PaCO2 variations, the differences between two
consecutive PaCO2 (delta PaCO2) values were computed
for each patient between the initial value and the 15-min
value, between the 15- and 30-min values, between the
30- and 45-min values, and finally between the 45- and
60-min values. Delta EtCO2 were computed to assess
EtCO2 variations according to the same procedure.
The PaCO2-EtCO2 gradient (Pa-E′CO2) was computed
for each patient with the pair of values recorded at
the beginning of the NIV session and at 15, 30, 45 and
60 min after the initiation of NIV. The number ofPa-E′CO2 values of more than ±10 mmHg was reported.
The ratio of this number over the total number of
measurements represents the proportion of clinically
unacceptable EtCO2 values. The treshold of 10 mmHg
to consider Pa-E′CO2 as clinically acceptable or not was
an arbitrary choice.
All statistical analyses were performed using MedCalc
Statistical Software version 12.7.2 (MedCalc Software,
Ostend, Belgium). Considering the small number of in-
cluded patients, non-normal distribution of the results
was assumed. All results are given as median [25th and
75th percentile].
The agreement between delta PaCO2 and delta EtCO2
was assessed by the Bland and Altman method adjusted
for the effect of repeated measurements. The differences
between each deltaPaCO2 and deltaEtCO2 values were
also computed. The percentage of differences higher
than 5 mmHg was reported as they were arbitrarily con-
sidered as clinically unacceptable values.
Agreement between PaCO2 and EtCO2 absolute values
was assessed using the Bland and Altman method ad-
justed for the effects of repeated measurements. Expira-
tory CO2 to PaCO2 agreement for values obtained after
active and passive complete expirations was also com-
puted with the Bland and Altman method adjusted for
the effects of repeated measurements. The gradient be-
tween expiratory CO2 and PaCO2 was computed with
the values obtained after active and passive complete ex-
pirations respectively. Clinically unacceptable values were
arbitrarily defined as values above 10 mmHg. The proportions
of clinically unacceptable gradients recorded were compared
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and passive complete expiration by chi-square test. p <
0.05 was considered as statistically significant.
Results
The whole 45-min protocol could be applied to ten pa-
tients. In one patient (patient number 4), the NIV treat-
ment had to be interrupted after 45 min because of
intolerance. In this patient, the second set of active and
passive expiratory manoeuvers was performed after
45 min instead of 1 h, immediately before stopping
NIV. Overall, 54-paired data sets of PaCO2 and EtCO2
from 11 patients (seven men/four women) could be re-
corded and were included in the analysis. Patients’ demo-
graphic and clinical data are given in Table 1. Among the
11 included patients, eight patients had chronic ob-
structive pulmonary disease (COPD) of various severity
(Table 1). Median age was 68 [62 and 77] years old and
median SAPS II score was 43 [34 and 44]. Initial blood
gas analysis, respiratory rate, inspired fraction of oxygen
(FIO2), PaO2/FIO2 ratio, and initial ventilator settings dur-
ing NIV are mentioned in Table 2.
During the study period, PaCO2 ranged from 39 to
80 mmHg, and EtCO2 from 12 to 68 mmHg. At the time
of the measurements, delivered inspiratory volume was
724 [597–896] ml and delivered minute ventilation was
18.6 [14.0-22.7] l/min. When assessing the agreement
between EtCO2 and PaCO2 gradients between two con-
secutive measurements, 43 paired data sets could be
analyzed. The bias was −0.3 mmHg and the limits of
agreement were −17.8 and +17.2 mmHg. The Bland and
Altman graphic representation is displayed in Figure 3.Table 1 Patient’s characteristics and clinical information.
Patient
number
Sex Age
[years]
BMI
[kg/m2]
SAPS 2
score
Cause of acute respira
1 F 52 25.3 24 COPD exacerbation
2 M 80 22.9 43 Chest trauma with multi
3 M 68 24.5 58 Pneumonia
4 M 59 42.6 44 Acute lung injury (bacte
5 M 77 29.3 43 Pneumonia
6 M 77 29.4 43 Acute lung injury (pancr
7 M 63 29.4 31 COPD exacerbation
8 M 77 26.1 36 Acute lung injury (perito
9 F 71 22.0 45 COPD exacerbation
10 F 61 17.2 42 COPD exacerbation
11 F 62 21.5 32 Central hypoventilation
Median 68 25.3 43
Centile 25 62 22.5 34
Centile 75 77 29.4 44
F, female; M, male; FEV1, forced expiratory volume in 1 s; COPD, chronic obstructiveSixteen of 43 differences (37%) between delta PaCO2 and
delta EtCO2 were higher than 5 mmHg.
When assessing agreement between PaCO2 and EtCO2
absolute values, bias was 14.7 mmHg and the limits of
agreement were −6.6 and 36.1 mmHg (Figure 4). The
Bland and Altman graphic representation is displayed in
Figure 4 both for COPD patients and non-COPD pa-
tients. Pa-E′CO2 was 12.4 [8.6-20.2] mmHg in median
but very high values were documented in some patients
(maximal value of 42.7 mmHg) and non-physiologic
slightly negative values were observed in one patient
(Figure 5). The number of clinically unacceptable values
for Pa-E′CO2 was 35/54 (65%).
When we compared agreements between PaCO2, con-
comitant EtCO2, and expired CO2 after active and passive
expiration maneuvers, we had 22-paired data available for
each comparison. The bias was respectively 15.7, 9.9, and
9.8 mmHg. Bland-Altmann plots for active and passive
expiration maneuvers are displayed in Figure 6A,B re-
spectively. The number of clinically unacceptable gradient
values was not different between the three measurements
(respectively, 13 (60%), 9 (41%), and 9 (41%), p = 0.37).
Discussion
Our results show that, in patients suffering from hyper-
capnic acute respiratory failure, measuring EtCO2 by a
dedicated naso-buccal sensor during NIV was inaccurate
to predict either PaCO2 variation over time or the ab-
solute PaCO2 value. Adding complete passive or ac-
tive expiratory maneuvers to expiratory CO2 measurements
did not significantly improve the reliability of PaCO2
prediction.tory failure Respiratory
comorbidity
FEV1 (% of
predicted value)
GOLD
classification
COPD 36 III
ple rib fractures None
COPD 43 III
rial peritonitis) COPD 57 II
COPD 32 III
eatitis) None
COPD 33 III
nitis) None
COPD Not available Not available
COPD 28 IV
(analgesia-sedation) COPD 54 II
pulmonary disease; BMI, body mass index.
Table 2 Respiratory rate, blood gas analysis at inclusion, and main initial ventilator settings
Patient
number
RR
[cycles/min]
SaO2 [%] pH PaCO2
[mmHg]
Bicarbonates
[mmol/L]
PaO2
[mmHg]
FIO2 PaO2/FIO2
ratio [mmHg]
Initial IPAP
[cmH2O]
Initial EPAP
[cmH2O]
1 12 93 7.41 45 27.7 62 0.28 159 15 10
2 17 92 7.38 52 29.6 64 0.35 148 12 7
3 16 88 7.46 45 31.1 53 0.5 89 14 6
4 41 91 7.41 55 34.7 58 0.35 158 12 7
5 21 94 7.32 80 39.8 67 0.4 200 20 8
6 30 99 7.41 55 34.0 112 0.4 138 12 7
7 27 92 7.42 61 38.8 62 0.5 123 8 5
8 29 91 7.40 50 30.7 61 0.5 101 11 6
9 25 90 7.33 58 29.4 58 0.4 145 15 6
10 28 95 7.37 58 32.5 75 0.35 165 12 6
11 20 92 7.47 51 36.7 59 0.3 171 15 6
Median 25 92. 7.41 55.3 32.5 62 0.4 148 12 6
Centile 25 19 91 7.37 51 30.2 58 0.35 131 12 6
Cetile 75 29 93 7.42 58 35.7 65 0.45 162 15 7
RR, respiratory rate; SaO2, oxygen saturation in arterial blood; PaCO2, carbon dioxide partial pressure in arterial blood; PaO2, oxygen partial pressure in arterial blood gas;
PaO2/FIO2, oxygen partial pressure in arterial blood gas over inspired fraction of oxygen ratio; IPAP, set inspiratory pressure; EPAP, set expiratory pressure.
Piquilloud et al. Annals of Intensive Care  (2015) 5:2 Page 5 of 8Before discussing the results in more details, we must
acknowledge the following limitations of our study. First,
only a small number of patients were included. However,
a high number of paired EtCO2 and PaCO2 could be an-
alyzed. As the correlation was poor with very high limits
of agreements, it is unlikely that increasing the number
of patients would have significantly modified the results.
Second, this study used a specific system to measure-15 -10 -5
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Figure 3 Bland-Altman plot of agreement between delta PaCO2 and d
and delta EtCO2. PaCO2, CO2 partial pressure in arterial blood; EtCO2, end-
non-COPD patients values; COPD, chronic obstructive pulmonary diseas
of agreement.EtCO2 and we cannot exclude that using another device
could have yielded different results. Third, only one EtCO2
value was recorded at each time. Even if the quality of the
corresponding capnogram was carefully checked, we can-
not exclude that averaging the values of several respiratory
cycles could have provided slightly different results. How-
ever, as airway resistance usually not varies between one
breath and the following, this effect, if present, should be0 5 10 15
Hg] and deltaEtCO2 [mmHg]
Mean
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Figure 4 Bland-Altman plot of agreement between PaCO2 and EtCO2. Bland-Altman plot of agreement between PaCO2 and EtCO2. PaCO2,
CO2 partial pressure in arterial blood; EtCO2, end-tidal CO2; circle markers, COPD patients values; square markers, non-COPD patients values; COPD,
chronic obstructive pulmonary disease. The horizontal lines represent the bias and the upper and lower limits of agreement.
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or other ventilators, e.g., ICU ventilators equipped with
inspiro-expiratory circuits, might also lead to different re-
sults. Fifth, during the active and passive complete expir-
ation maneuvers, some patients could potentially not have
emptied their lungs enough to reach the residual volume
because of maneuver intolerance or because they had to
expire through the breathing circuit against the set PEEP.Figure 5 Evolution over time of PaCO2-EtCO2 gradient for all the pati
gradient for all the patients. PaCO2, CO2 partial pressure in arterial blood; E
COPD patients.Thus, expired CO2 values might not truly reflect expired
CO2 at residual lung volume. Finally, we cannot exclude
that different results could have been found if we had
measured EtCO2 after stopping NIV treatment. However,
as, in clinical practice, it can be difficult or even dangerous
to interrupt NIV treatment in patients suffering from
acute respiratory failure, we did not test this alternative
approach.ents. This figure shows the evolution over time of PaCO2-EtCO2
tCO2, end-tidal CO2. Patient numbers 1, 3, 4, 5, 7, 9, 10, and 11 are
AB
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Figure 6 Bland-Altman plot of agreement between PaCO2
and expired CO2 after active and passive maximal expiration
maneuvers. A Bland-Altman plot of agreement between PaCO2
and expired CO2 after active maximal expiration maneuver (ExPA).
B Bland-Altman plot of agreement between PaCO2 and Expired CO2
after passive maximal expiration maneuver (ExPP). PaCO2, CO2 partial
pressure in arterial blood. In both figures, the horizontal lines
represent the bias and the upper and lower limits of agreement.
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anesthetized patients [7] to monitor PaCO2 and ventila-
tion, although many limitations have been recognized,
particularly for patients suffering from chronic respiratory
diseases (increased VD/VT ratio [8], airflow limitation)
or hemodynamic instability leading to ventilation-perfusion
mismatches [7,9]. Nasal EtCO2 has been successfully
used to monitor normocapnic patients with almost healthy
lungs undergoing regional anesthesia or recovering
from general anesthesia [10]. In line with the results of
the present study, two studies performed in spontan-
eously breathing patients suffering from acute respira-
tory failure found poor agreement between EtCO2 and
PaCO2 values [11,12]. Oppositely, in more stable and tra-
cheotomized patients, EtCO2 values were closer to PaCO2
values [13].In contrast to our results (see Figure 4), in this last
study [13], the agreement between EtCO2 and PaCO2
was better in non-COPD patients than in those suffering
from COPD. This last point suggests that during NIV,
physiopathological reasons probably do not explain by
themselves the poor performances of EtCO2 measure-
ment. A possible explanation for the poor agreement we
observed between EtCO2 and PaCO2 during NIV could
be the presence of a high airflow and of significant and
often variable leaks during NIV that may have caused
sampled expiratory gas dilution.
To try to overcome the expected limitation of EtCO2
measurement to assess PaCO2 absolute values and based
on the assumption that, in the absence of major haemo-
dynamic instability and of bronchodilatator administra-
tion, Pa-E′CO2, even if often unpredictable, might be
sufficiently constant over an hour in a given patient to
enable the tracking of PaCO2 evolution, we assessed the
time evolution of EtCO2 and PaCO2. This approach
clearly reduced the bias, but the wide limits of agree-
ment preclude its clinical use. Of course, we cannot ex-
clude that physiological reasons, as alveolar recruitment
occurring during NIV, could have decreased the VD/VT
ratio and contibutated to the poor performance of
EtCO2 variations to assess PaCO2 variations during NIV.
However in this situation, EtCO2 values would have
been closer to PaCO2 values at the end of the 1-h NIV
treatment, which was not the case.
To try to better assess PaCO2, we also attempted to
sample gas closer to the alveolar compartment by meas-
uring expiratory CO2 at the end of a ‘complete’ expiration
(either active or passive) [14] but this approach was also
disappointing. Again, this observation contrasts with a
study on stable tracheostomized patients [13] and under-
lines that performing reliable complete expiration maneu-
vers in acutely ill patients is very difficult.
The present study suggests that other technologies
should be considered to non-invasively assess PaCO2
and PaCO2 over time during NIV. Even if the reliability of
using transcutaneous CO2 monitoring to assess PaCO2 in
case of acute respiratory failure is still contoversial [15,16],
recent technological improvements in the transcutane-
ous CO2 monitoring technology suggest that this tech-
nique could be of interest to monitor PaCO2 during NIV.
This hypothesis, however, should be formally explored
prospectively.
Conclusions
When a naso-buccal sensor is used, major variations of
Pa-E′CO2 along time and poor limits of agreements be-
tween EtCO2 and PaCO2 preclude the use of EtCO2
measurement to predict PaCO2 or its variation over time
during NIV delivered for acute hypercapnic respiratory
failure. Adding complete expiration maneuvers, whether
Piquilloud et al. Annals of Intensive Care  (2015) 5:2 Page 8 of 8passive or active did not improve PaCO2 prediction
using EtCO2 during NIV. The optimal approach to non-
invasively monitor PaCO2 during NIV in patients with
acute hypercapnic respiratory failure remains to be
determined.
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